UAE: Two Phase 3 thalassemia clinical trials to begin in Abu Dhabi, aim to develop new treatment

UAE: Two Phase 3 thalassemia clinical trials to begin in Abu Dhabi, aim to develop new treatment

The blood disorders are among the world’s most common genetic diseases, and are highly prevalent in the region

Published: Mon 13 Feb 2023, 1:02 PM

In another milestone in the health sector, the UAE Capital is set to begin two global clinical trials to transform the way thalassemia is being treated.

Thalassemia is a group of inherited blood disorders that affect the body’s production of haemoglobin and red blood cells. It is among the world’s most common genetic diseases and is highly prevalent in the region.

Under the supervision and support of the Department of Health – Abu Dhabi (DoH), Energise and Energise-T – two Phase 3 trials for adult patients with thalassemia, aim to test the effectiveness and safety of a new drug called Mitapivat.

Conducted at Burjeel Medical City in Abu Dhabi, the clinical trials offer new hope for thalassemia patients in the country. They will provide an opportunity for eligible patients in the region to get screened and be part of studies aimed at developing new thalassemia treatments.

The trials will be conducted in collaboration with several centres and multiple sites across the US, the EU, and Asia, enabling access to state-of-the-art therapies from the outset of clinical development.

Mitapivat is approved in the